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Multiple sclerosis (MS) is a debilitating neuroimmunological and neurodegenerative disorder. Despite substantial
evidence for polygenic inheritance of the disease, the major histocompatibility complex is the only region that
clearly and consistently demonstrates linkage and association in MS studies. The goal of this study was to identify
additional chromosomal regions that harbor susceptibility genes for MS. With a panel of 390 microsatellite markers
genotyped in 245 U.S. and French multiplex families (456 affected relative pairs), this is the largest genomic screen
for MS conducted to date. Four regions met both of our primary criteria for further interest (heterogeneity LOD
[HLOD] and Z scores 12.0): 1q ( ; ), 6p ( ; ), 9q ( ;HLODp 2.17 Zp 3.38 HLODp 4.21 Zp 2.26 HLOD Zp
), and 16p ( ; ). Two additional regions met only the Z score criterion: 3q (2.71 HLODp 2.64 Zp 2.05 Zp
) and 5q ( ). Further examination of the data by country (United States vs. France) identiﬁed one2.39 Zp 2.17
additional region demonstrating suggestive linkage in the U.S. subset (18p [ ]) and two additionalHLODp 2.39
regions generating suggestive linkage in the French subset (1p [ ] and 22q [ ]). Ex-HLODp 2.08 HLODp 2.06
amination of the data by human leukocyte antigen (HLA)–DR2 stratiﬁcation identiﬁed four additional regions
demonstrating suggestive linkage: 2q ( in the U.S. DR25 families), 6q ( in the FrenchHLODp 3.09 HLODp 3.10
DR25 families), 13q ( in all DR2+ families and in the U.S. DR2+ families), andHLODp 2.32 HLODp 2.17
16q ( in all DR2+ families and in the U.S. DR2+ families). These data suggest severalHLODp 2.32 HLODp 2.13
regions that warrant further investigation in the search for MS susceptibility genes.
Introduction
Multiple sclerosis (MS [MIM 126200]) is a debilitating
neuroimmunological and neurodegenerative disorder.
Plaques and lesions formed in the CNS of patients with
the disease impair saltatory conduction along axons that
is necessary for normal functioning of nerve impulses.
MS is a clinically heterogeneous disease with a range of
symptoms that present as episodic or progressive neu-
rological impairments. The disease is common in young
adults and affects females two to three times more fre-
quently than males. Despite the devastating impairment
and deterioration seen in MS, lifespan of affected indi-
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viduals is only slightly shortened—creating a signiﬁcant
impact on the quality of life for patients and on national
healthcare systems.
Although little is known about the underlying etiol-
ogy of the disease,MS is physiologically an inﬂammatory
disorder resulting from an autoimmune response directed
against CNS antigens, particularly myelin proteins. MS
exhibits several characteristics common to autoimmune
disorders, including polygenic inheritance, evidence of
disease-associated environmental exposure, and partial
susceptibility conferred by a human leukocyte antigen
(HLA)–associated gene (Barcellos et al. 2002).
Perhaps it is not surprising that the strongest andmost
consistent ﬁnding for linkage to MS is at chromosome
6p21, the location of the major histocompatibility com-
plex (MHC) containing HLA. To date, the MHC is the
only region that clearly and consistently demonstrates
linkage and association with MS (Haines et al. 1996,
1998; Sawcer et al. 1996; Yaouanq et al. 1997). The
MHC has been estimated to account for 10%–50% of
the genetic component of MS susceptibility, at least
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Table 1
Description of the Data Set
FAMILIES
NO. OF
FAMILIES
NO. OF AFFECTED NO. OF FAMILIES DESIGNATED
Individuals Sib Pairs Other Relative Pairs HLA-DR2 HLA-DR2
U.S. 151 383 242 88 83 31
French 94 204 102 24 28 35
All 245 587 344 112 111 66
NOTE.—Families were designated HLA-DR2 if every affected individual carried at least one HLA-DR2
allele and were designated HLA-DR2 if no affected individuals carried an HLA-DR2 allele.
in white populations of northern European descent
(Haines et al. 1998; Dyment et al. 2004). It appears that
the association with the HLA-DR2 allele largely ex-
plains this linkage signal (Haines et al. 1998; Barcellos
et al. 2002). However, the exact mechanism by which
a gene or genes in the MHC increase disease risk has
yet to be determined.
The clinical heterogeneity and complex etiology of
MS have been confounding factors in studies of the
disease. Despite these complexities, it is clear that genes
play a vital role in the susceptibility toMS. In an attempt
to identify regions that harbor MS loci, numerous re-
search groups have conducted genomic screens (Ebers et
al. 1996; Haines et al. 1996; Sawcer et al. 1996,2002;
Kuokkanen et al. 1997; Broadley et al. 2001; Coraddu
et al. 2001; Akesson et al. 2002; Ban et al. 2002; Eraksoy
et al. 2003; Hensiek et al. 2003; Dyment et al. 2004).
These studies have identiﬁed 160 genomic regions with
potential disease loci, but little overlap has been seen
between studies. These results suggest that the existence
of genes with strong individual effects is unlikely.
Onemajor complication for linkage analysis is genetic
heterogeneity—the presence of different loci that pro-
duce similar disease phenotypes. Underlying genetic het-
erogeneity in MS has likely masked the effects of true
loci in many linkage studies. An approach that attempts
to overcome loss of power due to heterogeneity is con-
ditional analysis with covariates. By accounting for
regions of known linkage (e.g., the MHC) with strati-
ﬁcation or weighting schemes, conditional analysis can
identify additional regions of interest. Conditional anal-
ysis can also provide evidence for interactive effects of
loci, potentially providing increased power for detection
of epistatic genes in complex diseases such as MS.
The goal of this study was to identify chromosomal
regions that harbor MS susceptibility genes. We con-
ducted a collaborative genomic screen using an ex-
panded data set of U.S. and French families. With 245
multiplex families (456 affected relative pairs) and 390
microsatellite markers, this is the largest genomic screen
for MS conducted to date.
Material and Methods
Families
The data set used in this study consisted of U.S. fam-
ilies from a genomic screen published elsewhere (Haines
et al. 1996), 66 additional U.S. families, and 94 French
families. The full data set included 245 multiplex fam-
ilies, consisting of 587 affected individuals, 344 affected
sib pairs, 112 other affected relative pairs, and a total
of 1,085 samples (table 1).
U.S. families were ascertained by the University of
California at San Francisco (UCSF). All affected U.S.
family members were examined or had their medical
records reviewed by one of the authors (S.L.H.). Families
were extended through all affected ﬁrst-degree relatives,
if possible. French families were collected through a na-
tional network of university and community hospitals
and private practitioners. All affected French family
members were examined by a clinician from one of three
centers (Paris, Rennes, or Toulouse).
All protocols were approved by the appropriate in-
stitutional review boards, and all individuals provided
informed consent before participating in the study. Pos-
itive family histories were investigated by direct contact
with other family members, by request for medical re-
cords, and by clinical examination, laboratory testing,
or paraclincial studies (magnetic resonance imaging
[MRI] scanning and evoked-response testing). Consis-
tent and stringent clinical criteria were applied as de-
scribed elsewhere (Goodkin et al. 1991; Haines et al.
1996). Individuals were placed into one of four cate-
gories: deﬁnite MS, probable MS, possible MS, and no
evidence of MS. Only individuals categorized as deﬁnite
MS cases were considered as affected in the analysis.
To account for possible heterogeneity, the data were
examined for differences by country (United States vs.
France) and HLA-DR2 genotype (HLA-DR2 vs. HLA-
DR2). Families were designated HLA-DR2 if every
affected individual carried at least one HLA-DR2 allele
and were designated HLA-DR2 if no affected individ-
uals carried an HLA-DR2 allele (table 1).
1072 Am. J. Hum. Genet. 75:1070–1078, 2004
Figure 1 Two-point HLOD scores for the overall data set. aMarshﬁeld genetic map (see Marshﬁeld Web site).
Molecular Analysis
After informed consent was obtained, blood samples
were collected from each individual. Genomic DNAwas
extracted from blood, by use of standard procedures as
described elsewhere (Vance 1998). All samples were
coded and stored at 4C until used.
Marker primer sequences were obtained from the Ge-
nome Database (see Genome DatabaseWeb site) or were
designed with Primer3 software (see Primer3 Web site)
and were synthesized by Invitrogen Life Technologies.
Ampliﬁcation was performed in a PCR Express machine
(ThermoHybaid) under the following conditions: 94C
for 4 min; 94C for 15 s, annealing temperature for 30
s, and 72C for 45 s (35 cycles); and 72C for 4 min.
PCR products were denatured for 3 min at 95C and
were run on a 6% polyacrylamide gel (Sequagel-6 [Na-
tional Diagnostics]) for ∼1 h at 75 W. Gels were stained
with a SybrGold rinse (Molecular Probes) and were
scanned with the Hitachi Biosystems FMBIOII laser
scanner. Genotypes for HLA-DR in the U.S. families
were determined at UCSF by use of nonradioactive
PCR-sequence–speciﬁc oligonucleotide probes (PCR-
SSOP). Genotypes for HLA-DR in the French families
were determined using reverse dot blot hybridization.
Marker order and intermarker distance were obtained
from linkage reference maps (see Marshﬁeld and de-
CODE Web sites). The average intermarker distance for
the screen was !10 cM. The Vanderbilt and Duke lab-
oratories each genotyped a subset of markers on the
complete set of DNA samples. Laboratory personnel
were blinded to pedigree structure, affected status, and
location of quality-control samples. Duplicate quality-
control samples (three unblinded CEPH individuals and
four blinded controls) were placed both within and
across plates, and equivalent genotypes were required to
ensure accurate genotyping.
Allele frequencies were calculated from the genotyped
founders in each family. Hardy-Weinberg calculations
were performed for each marker, and Mendelian incon-
sistencies were identiﬁed using PedCheck (O’Connell
and Weeks 1998). Suspect genotypes were reread and/
or rerun. All microsatellites were required to have 185%
of possible genotypes. Veriﬁcation of relationships be-
tween pairs of samples within families was performed
using RELPAIR (Epstein et al. 2000). Markers and
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Figure 2 Two-point HLOD scores for the HLA-DR2 subsets. aMarshﬁeld genetic map (see Marshﬁeld Web site).
samples failing to pass quality-control measures were
dropped from the analysis.
Statistical Analysis
Both model-based and model-free analyses were per-
formed. Parametric (model-based) analyses were con-
ducted using autosomal dominant and autosomal re-
cessive models with disease-allele frequencies of 0.01 and
0.20, respectively, to model a common susceptibility al-
lele. A penetrance value of 0.95 was used for both dom-
inant and recessive models, and individuals with no ev-
idence of MS were coded as normal for these analyses.
Two-point LOD scores were calculated by FASTLINK
(Cottingham et al. 1993; Schaffer et al. 1994), and
heterogeneity LOD (HLOD) scores were calculated by
HOMOG (Smith 1963; Ott 1986). Two-point HLOD
scores for the overall data set, the HLA-DR2 subsets,
and the HLA-DR2 subsets are provided in ﬁgures 1,
2, and 3, respectively.
Multipoint model-free analyses were performed using
the “score pairs” option and the exponential model
(Kong and Cox 1997) in Allegro (Gudbjartsson et al.
2000). Multipoint results are reported as Z scores. Be-
cause the HLA-DR2 allele is known to be associated
withMS, the interaction betweenHLA and other regions
was tested by correlation between family nonparametric
linkage (NPL) values in the 236 nuclear families with at
least one affected sib pair.
The criterion to consider a region as interesting was
at least one marker with a maximum HLOD 12.0 or a
multipoint Z score 12.0. Because other research groups
have advocated the use of more liberal criteria in ge-
nomic screens, we also report markers generatingHLOD
or Z scores 11.5 and have made the complete set of
scores available at the Vanderbilt Center for Human Ge-
netics Research Web site.
We performed a number of statistical tests on micro-
satellite markers, disease models, and subsets, raising
concern about multiple comparisons. The level of cor-
rection necessary to account for these factors is a topic
of substantial debate, and it is not currently clear how
to select an appropriate level of corrections for this study
design. We therefore have chosen to present the results
of this study without correction for multiple tests. To
gain some idea of a signiﬁcance level for our data set,
we performed a simulation using the observed family
structures. The value of the threshold for HLOD scores
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Figure 3 Two-point HLOD scores for the HLA-DR2 subsets. aMarshﬁeld genetic map (see Marshﬁeld Web site).
for a genomewide type I error of 1% was 1.86, under
the hypothesis of no linkage. The value of the threshold
for the model-free statistic Z for a genomewide type I
error of 5% was 3.56, under the hypothesis of no
linkage.
Results
Overall Analysis
Four regions met the primary criterion for further in-
terest in both two-point and multipoint calculations
(HLOD and Z scores 12.0): 1q ( ;HLODp 2.17 Zp
), 6p ( ; ), 9q (3.38 HLODp 4.21 Zp 2.26 HLODp
; ), and 16p ( ; )3.55 Zp 2.71 HLODp 2.64 Zp 2.05
(tables 2 and 3). Seven regions (1p, 2q, 6q, 13q, 16q,
18p, and 22q) generated only HLOD scores 12.0, and
two regions (3q and 5q) generated only Z scores 12.0.
The use of a more liberal criterion of an HLOD score
11.5 identiﬁed eight additional regions in the two-point
analysis (2p, 3p, 3q, 4p, 4q, 7p, 12q, and 15q), whereas
a more liberal criterion of a Z score 11.5 identiﬁed three
additional regions in the multipoint analysis (2p, 10q,
and 18p).
Site Stratiﬁcation
Further examination of the data by country (United
States vs. France) identiﬁed three regions demonstrating
suggestive linkage in the U.S. subset: 6p (HLODp
), 9q ( ), and 18p ( )3.30 HLODp 2.32 HLODp 2.39
(table 2). Two of these three regions (6p and 9q) were
also identiﬁed in examination of the overall data set, as
discussed above. Site stratiﬁcation also identiﬁed three
regions generating suggestive linkage in the French sub-
set only: 1p ( ), 16p ( ), andHLODp 2.08 HLODp 2.64
22q ( ).HLODp 2.06
HLA-DR2 Stratiﬁcation
Further examination of the data identiﬁed markers
generating suggestive HLOD scores after HLA-DR2
stratiﬁcation in seven regions: 2q ( in theHLODp 3.09
U.S. DR2 families), 6p ( in all DR2HLODp 2.24
families), 6q ( in the French DR2 fam-HLODp 3.10
ilies), 9q ( in all DR2 families), 13qHLODp 2.05
( in all DR2 families andHLODp 2.32 HLODp
in the U.S. DR2 families), 16q (2.17 HLODp 2.32
in all DR2 families and in the U.S.HLODp 2.13
DR2 families), and 18p ( in all DR2HLODp 2.25
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Table 2
Regions with Two-Point HLOD Scores 12.0
Chromosome and
Locationa (cM) Marker Data Setb HLODc
1p:
45 D1S552 3 2.08d
1q:
268 D1S547 1 2.17d
2q:
200 D2S1384 7 3.09e
6p:
34 D6S1959 4 2.24d
44 HLA-DR 1, 2 4.21e, 3.30d
6q:
119 D6S474 8 3.10d
9q:
136 D9S282 1, 2, 4 3.55d, 2.32d, 2.05d
13q:
6 D13S175 4, 5 2.32d, 2.17d
16p:
8 D16S2622 3 2.64d
16q:
100 D16S516 4, 5 2.32d, 2.13d
18p:
19 D18S391 2 2.39e
28 D18S843 6, 7 2.25e, 2.84e
22q:
29 D22S689 3 2.06d
a Marshﬁeld genetic map (see Marshﬁeld Web site).
b 1 p All families; 2 p only U.S. families; 3 p only French
families; 4p all DR2 families; 5p U.S. DR2 families; 6p all
DR2 families; 7 p U.S. DR2 families; 8 p French DR2
families.
c The highest HLOD scores are indicated in bold italics.
d Calculated under a recessive model.
e Calculated under a dominant model.
Table 3
Regions with Multipoint Z Scores 12.0
Chromosome
Locationa
(cM) Marker Z
1q 268 D1S547 3.38
3q 216 D3S2418 2.39
5q 139 D5S816 2.17
6p 34 D6S1959 2.26
9q 136 D9S282 2.71
16p 8 D16S2622 2.05
a Marshﬁeld genetic map (seeMarshﬁeldWeb site).
families and in the U.S. DR2 families)HLODp 2.84
(table 2). Four of these regions (2q, 6q, 13q, and 16q)
were identiﬁed in only HLA-DR2–stratiﬁed subsets.
Discussion
Genetic linkage analysis has proven to be successful in
locating Mendelian disease genes, but whole-genome
screens have been less successful in locating genes for
complex genetic diseases such as MS. Rarely does any
region reach a single-stage signiﬁcance level, which sug-
gests that a two-stage design requiring conﬁrmation in
at least one additional data set is necessary to declare
linkage. Our results hold true with this general pattern,
but several of the regions identiﬁed in this screen do
recapitulate signiﬁcant linkage suspected by other
groups. Our large data set and stringent criteria for iden-
tifying regions of interest (HLOD and/or Z scores 12.0)
suggest several regions of linkage for MS.
Not surprisingly, a marker in the HLA-DR region on
chromosome 6p21 generated the highest two-point
LOD score ( ) and one of the highest mul-HLODp 4.21
tipoint LOD scores ( ) for the entire screen,Zp 2.26
conﬁrming the overwhelming evidence of a risk factor
in this region (Haines et al. 1996; Sawcer et al. 1996;
Kuokkanen et al. 1997; Akesson et al. 2002).
The strongest evidence of linkage to a non-MHC re-
gion in the overall data set was for 9q33 (HLODp
; ). The initial Multiple Sclerosis Genetics3.55 Zp 2.71
Group (MSGG) screen, MSGG follow-up study, and
recent screens in Nordic sib pairs and Turkish families
also demonstrate moderate support for 9q, highlighting
the need for further investigation of this region (Haines
et al. 1996, 2002; Akesson et al. 2002; Eraksoy et al.
2003).
Another region of interest from this screen that is
supported by several lines of evidence is 1q. Marker
D1S547 in 1q43 met the criterion for further inter-
est in both two-point and multipoint calculations
( ; ). Nearby markers have alsoHLODp 2.17 Zp 3.38
demonstrated suggestive linkage and/or association in
several other MS screens using a variety of study pop-
ulations (Broadley et al. 2001; Ban et al. 2002; Goedde
et al. 2002; Sawcer et al. 2002; Laaksonen et al. 2003).
Another compelling piece of evidence for 1q is linkage
to this region in the autoimmune disorders rheumatoid
arthritis (Jawaheer et al. 2001) and systemic lupus er-
ythematosus (Shai et al. 1999), suggesting the presence
of a gene for general autoimmune processes. The 1q
region is also orthologous to a region suggested to con-
tain a risk factor for experimental autoimmune en-
cephalomyelitis (EAE) in the rat (Roth et al. 1999).
Chromosome 5q is another region of interest from
the screen that is supported by several lines of evidence.
Marker D5S816 in the 5q31 region met the multipoint
criterion for further interest, with a Z score of 2.17.
Linkage to the 5q region has also been suggested in
another recent MS screen (Broadley et al. 2001). Like
region 1q, 5q has been investigated for a risk factor in
other inﬂammatory and autoimmune disorders, includ-
ing Crohn disease (Rioux et al. 2001), type 1 diabetes
(Morahan et al. 2001), celiac disease (Greco et al. 1998;
Naluai et al. 2001), and asthma and allergy (Cookson
and Moffatt 2000). The 5q region is also orthologous
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to a region suggested to contain a risk factor for EAE
in the rat (Roth et al. 1999).
The initial MSGG screen on 52 families identiﬁed 19
regions that potentially harbor MS susceptibility loci
(Haines et al. 1996). Follow-up of these regions with
an expanded data set of 96 families continued to pro-
vide the strongest support for ﬁve regions: 6p21, 6q27,
12q23-24, 16p13, and 19q13 (Haines et al. 2002).
Three of these ﬁve regions continue to generate HLOD
scores 11.5 in this second-generation genomic screen of
245 families (6p21, 12q23-24, and 16p13), providing
consistent support for these regions in three of our stud-
ies to date.
Although evidence for region 19q13 has been con-
sistently seen in our families, there is decreased evidence
for this region in the current study. Despite this de-
creased evidence, 19q13 remains interesting for several
reasons. Outside of the MHC, 19q13 is the region
most consistently observed for linkage and/or associa-
tion with MS. At least ﬁve genomic screens, includ-
ing the initial MSGG screen and the present screen
( ), support at least moderate linkage toHLODp 1.44
an MS risk locus at 19q13 (Ebers et al. 1996; Haines
et al. 1996; Sawcer et al. 1996; Kuokkanen et al. 1997;
Coraddu et al. 2001). Numerous allelic association
studies also provide evidence of a risk locus in this re-
gion. In addition, there is substantial evidence that the
ApoE gene in this region modulates the severity and/or
progression of MS (Chapman et al. 1999, 2001; Evan-
gelou et al. 1999; Fazekas et al. 2000, 2001; Hogh et
al. 2000; Schmidt et al. 2002; Enzinger et al. 2004).
Further investigation will be necessary to conﬁrm and
identify a speciﬁc 19q13 disease locus.
As suggested in the literature, stratiﬁcation yielded
substantial increases in our linkage signals in several
deﬁned data sets (Leal and Ott 2000). In addition, four
regions yielded HLOD scores 12.0 only when HLA-
DR2 stratiﬁcation was performed: 2q was identiﬁed in
the U.S. DR2 families, 6q was identiﬁed in the French
DR2 families, and 13q and 16q were identiﬁed in both
the U.S. DR2 families and the overall set of DR2
families. Results in the 2q and 6q regions suggest effects
independent of HLA-DR, whereas results in the 13q and
16q regions suggest potential interactive effects with
HLA-DR. However, formal tests of correlations be-
tween NPL scores in families with at least one affected
sib pair ( ) and NPL scores for regions on chro-np 236
mosomes 1, 3, 5, 9, and 16 failed to detect any signif-
icant correlations.
It will be important to examine the regions identiﬁed
in this genomic screen in more detail by use of both
larger data sets and denser maps of markers. The advent
of high-density SNP maps now allows for very rapid
and accurate genotyping of large numbers of SNPs in
small regions, thus promoting high levels of information
extraction. Finer mapping studies with additional fam-
ilies are currently underway to further localize linkage
signals identiﬁed in this screen.
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